News
-
-
COMMUNIQUÉ DE PRESSE
NanoViricides, Inc. Has Filed its Quarterly Report - Subsequent Raise Has Fortified Fiscal Position
NanoViricides, Inc. files Form 10-Q for Q3 2025 with SEC, presents NV-387 as broad-spectrum antiviral drug addressing unmet medical needs. Company strengthens financial position with recent financings -
-
-
COMMUNIQUÉ DE PRESSE
Rockhaven Reports Multiple High-Grade Vein Exposures at its Klaza Gold-Silver Project, Yukon
Rockhaven Resources Ltd. reports high-grade gold-silver assay results from the 2025 exploration program at Klaza property, Yukon, advancing towards potential bulk sampling and economic studies -
COMMUNIQUÉ DE PRESSE
DeFi Technologies Announces Leadership Transition: Olivier Roussy Newton Resigns as CEO and Chairman; Co-Founder Johan Wattenström Appointed as Successor
DeFi Technologies announces leadership transition as Olivier Roussy Newton resigns as CEO and Chairman; Johan Wattenström appointed as successor. Company's growth and milestones under Roussy Newton's leadership highlighted -
COMMUNIQUÉ DE PRESSE
Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue
Jaguar Health, Inc. reports proof-of-concept trial shows crofelemer potential for MVID patients, financial results revealed, FDA meeting outcome, and upcoming investor webcast -
-
-